Could a common cancer drug help rare tumors? new trial aims to find out

NCT ID NCT05770102

Recruiting now Disease control Sponsor: Cancer Research UK Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests atezolizumab, a drug already approved for several cancers, in people with rare cancers that have high tumor mutational burden (TMB) or microsatellite instability (MSI). The goal is to see if the drug can shrink tumors or stop them from growing for at least 24 weeks. Up to 30 adults and children with these genetic markers will receive the drug every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab (Tecentriq)
What this could lead to: If it works, this could expand the use of an already-approved drug to treat more rare cancer types with specific genetic changes.
What could go wrong: This is an early-to-mid stage trial with only 30 participants, so results may not apply broadly. The drug may not work for all cancer types tested, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colorectal neoplasm endometrium neoplasm lymphoproliferative syndrome Lynch syndrome melanoma mismatch repair cancer syndrome neoplasm Neoplasms by Histologic Type Neoplasms by Site

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER COLORECTAL NEOPLASMS ENDOMETRIAL NEOPLASMS LYMPHOPROLIFERATIVE DISORDERS MALIGNANCY MALIGNANT NEOPLASM MELANOMA NEOPLASMS BY HISTOLOGIC TYPE NEOPLASMS BY SITE SOLID TUMOURS

Contacts and locations

Locations

Addenbrooke's Hospital
RECRUITING

Cambridge, CB2 OQQ, United Kingdom
Alder Hey Hospital
RECRUITING

Liverpool, L14 5AB, United Kingdom
Belfast City Hospital
NOT_YET_RECRUITING

Belfast, BT9 7AB, United Kingdom
Birmingham Children's Hospital
NOT_YET_RECRUITING

Birmingham, United Kingdom
Bristol Haematology and Oncology Centre
RECRUITING

Bristol, BS2 8ED, United Kingdom
Bristol Royal Hospital for Children
RECRUITING

Bristol, BS2 8BJ, United Kingdom
Cardiff Children's Hospital
NOT_YET_RECRUITING

Cardiff, CF14 4XW, United Kingdom
Churchill Hospital
RECRUITING

Oxford, OX3 7LE, United Kingdom
Clatterbridge Cancer Centre
RECRUITING

Metropolitan Borough of Wirral, CH63 4JY, United Kingdom
Freeman Hospital
RECRUITING

Newcastle, NE7 7DN, United Kingdom
Great North Children's Hospital
RECRUITING

Newcastle, NE1 4LP, United Kingdom
Great Ormond Street Hospital
RECRUITING

London, WC1N 3JH, United Kingdom
Guy's Hospital
RECRUITING

London, SE1 9RT, United Kingdom
John Radcliffe Hospital
RECRUITING

Oxford, OX3 9DU, United Kingdom
Leicester Royal Infirmary
RECRUITING

Leicester, LE1 5WW, United Kingdom
Royal Hospital for Children Glasgow
RECRUITING

Glasgow, G51 4TF, United Kingdom
Royal Manchester Children's Hospital
NOT_YET_RECRUITING

Manchester, M13 9WL, United Kingdom
Sheffield's Children's Hospital
RECRUITING

Sheffield, S10 2TH, United Kingdom
Southampton General Hospital
RECRUITING

Southampton, SO16 6YD, United Kingdom
The Beatson Hospital
RECRUITING

Glasgow, G12 OYN, United Kingdom
The Christie Hospital
RECRUITING

Manchester, M20 4BX, United Kingdom
The Royal Marsden Hospital
RECRUITING

Sutton, SM2 5PT, United Kingdom
University College London Hospital
RECRUITING

London, NW1 2BU, United Kingdom
University Hospital Birmingham
RECRUITING

Birmingham, B15 2TT, United Kingdom
Velindre Cancer Centre
RECRUITING

Cardiff, CF14 2TL, United Kingdom
Western General Hospital
RECRUITING

Edinburgh, EH4 2XU, United Kingdom
Weston Park Hospital
RECRUITING

Sheffield, S10 2SJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.